Michael Tanaka

Title(s)Clinical Professor, Hematology and Oncology
SchoolUniversity of California, Davis
Address?Cancer Ctr So, #3016
CA 95817
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Phase II Study of Dovitinib in Patients Progressing on Anti-Vascular Endothelial Growth Factor Therapy. Cancer Treat Res Commun. 2017; 10:21-26. Semrad TJ, Kim EJ, Tanaka MS, Sands J, Roberts C, Burich RA, Li Y, Gandara DR, Lara P, Mack PC. PMID: 28736761; PMCID: PMC5519297.
      View in: PubMed   Mentions: 11     Fields:    
    2. Long-Term Progression-Free Survival in a Patient with Locally Advanced, Unresectable Pancreatic Adenocarcinoma. Cureus. 2015 Dec 15; 7(12):e406. Dyer BA, Kahn LA, Matin M, Bold RJ, Tanaka MI, Monjazeb AM. PMID: 26824007; PMCID: PMC4725616.
      View in: PubMed   Mentions:
    3. Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results. Int J Clin Oncol. 2015 Jun; 20(3):518-24. Semrad T, Barzi A, Lenz HJ, Hutchins IM, Kim EJ, Gong IY, Tanaka M, Beckett L, Holland W, Burich RA, Snyder-Solis L, Mack P, Lara PN. PMID: 25091263; PMCID: PMC4318776.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    4. Escalating weekly doses of cetuximab and correlation with skin toxicity: a phase I study. Invest New Drugs. 2011 Aug; 29(4):680-7. Ho C, Sangha R, Beckett L, Tanaka M, Lau DH, Eisen DB, Burich RA, Luciw P, Khan I, Mack PC, Gandara DR, Davies AM. PMID: 20148348; PMCID: PMC4559347.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    5. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol. 2009 Sep; 64(4):777-83. Ramanathan RK, Belani CP, Singh DA, Tanaka M, Lenz HJ, Yen Y, Kindler HL, Iqbal S, Longmate J, Mack PC, Lurje G, Gandour-Edwards R, Dancey J, Gandara DR. PMID: 19169683.
      View in: PubMed   Mentions: 106     Fields:    Translation:HumansCTClinical Trials
    6. Population-based phase I trial of irinotecan and epirubicin. Am J Clin Oncol. 2008 Jun; 31(3):226-30. Lau D, Johl J, Huynh M, Davies A, Tanaka M, Lara P, Gandara D. PMID: 18525299.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    7. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008 Feb 01; 26(4):626-32. Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CD, Crowley JJ, Borden EC. PMID: 18235122.
      View in: PubMed   Mentions: 390     Fields:    Translation:HumansCTClinical Trials
    8. Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer. J Thorac Oncol. 2007 Dec; 2(12):1112-6. Davies AM, Ho C, Metzger AS, Beckett LA, Christensen S, Tanaka M, Lara PN, Lau DH, Gandara DR. PMID: 18090584.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    9. A phase II study of paclitaxel, carboplatin, and radiation with or without surgery for esophageal cancer. J Thorac Oncol. 2007 Feb; 2(2):153-7. Wang H, Ryu J, Gandara D, Bold RJ, Urayama S, Tanaka M, Goldberg Z, Follette D, Narayan S, Lau D. PMID: 17410032.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    10. Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. J Clin Oncol. 2006 Aug 01; 24(22):3542-7. Smalley SR, Benedetti JK, Williamson SK, Robertson JM, Estes NC, Maher T, Fisher B, Rich TA, Martenson JA, Kugler JW, Benson AB, Haller DG, Mayer RJ, Atkins JN, Cripps C, Pedersen J, Periman PO, Tanaka MS, Leichman CG, Macdonald JS. PMID: 16877719.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCTClinical Trials
    11. Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: a Southwest Oncology Group study. Invest New Drugs. 2006 Jul; 24(4):335-41. Whitehead RP, McCoy S, Macdonald JS, Rivkin SE, Neubauer MA, Dakhil SR, Lenz HJ, Tanaka MS, Abbruzzese JL, Southwest Oncology Group. PMID: 16683076.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    12. An evaluation of barriers to accrual in the era of legislation requiring insurance coverage of cancer clinical trial costs in California. Cancer J. 2004 Sep-Oct; 10(5):294-300. Martel CL, Li Y, Beckett L, Chew H, Christensen S, Davies A, Lam KS, Lau DH, Meyers FJ, O'donnell RT, Richman C, Scudder S, Tanaka M, Tuscano J, Welborn J, Wun T, Gandara DR, Lara PN. PMID: 15530258.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    13. Population-based maximum tolerated dose of irinotecan and carboplatin. Oncology (Williston Park). 2003 Jul; 17(7 Suppl 7):11-6. Wild CA, Wang SE, Gandara DR, Lara PN, Meyers FJ, Tanaka M, Houston J, Lauder J, Lau DH. PMID: 12886868.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    14. Phase I trial of gemcitabine and paclitaxel in advanced solid tumors. Cancer Invest. 2003; 21(1):7-13. Lim N, Lara PN, Lau DH, Edelman MJ, Tanaka M, al-Jazayrly G, Houston J, Lauder I, Gandara DR. PMID: 12643004.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    15. Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study. Ann Oncol. 2002 Oct; 13(10):1576-82. Rothenberg ML, Benedetti JK, Macdonald JS, Seay TE, Neubauer MA, George CS, Tanaka MS, Giguere JK, Pruitt BT, Abbruzzese JL. PMID: 12377645.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    16. Premedication strategy for weekly paclitaxel. Cancer Invest. 2002; 20(5-6):666-72. Quock J, Dea G, Tanaka M, Gandara D, Lara P, Lau D. PMID: 12197222.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    17. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol. 2001 Mar 15; 19(6):1728-33. Lara PN, Higdon R, Lim N, Kwan K, Tanaka M, Lau DH, Wun T, Welborn J, Meyers FJ, Christensen S, O'Donnell R, Richman C, Scudder SA, Tuscano J, Gandara DR, Lam KS. PMID: 11251003.
      View in: PubMed   Mentions: 236     Fields:    Translation:Humans
    18. Weekly 24-hour continuous infusion interleukin-2 for metastatic melanoma and renal cell carcinoma: a phase I study. J Immunother (1991). 1991 Feb; 10(1):57-62. Perez EA, Scudder SA, Meyers FA, Tanaka MS, Paradise C, Gandara DR. PMID: 2012799.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    19. Conjugated estrogen for platelet dysfunction associated with liver disease. N Engl J Med. 1988 Jun 09; 318(23):1543. Perez EA, Tanaka M, Gandara DR. PMID: 2835682.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    20. Changes of plasminogen activator in human uterine tissue induced by intrauterine contraceptive devices. Contraception. 1983 Feb; 27(2):131-40. Shaw ST, Macaulay LK, Sun NC, Tanaka MS, Roche PC. PMID: 6682747.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    21. Plasminogen activator in human uterine tissue--relationship to location of sampling and time in ovarian cycle. Biochem Med. 1980 Oct; 24(2):170-8. Shaw ST, Macaulay LK, Tanaka MS, Hohman WR, Moyer DL, Sun NC. PMID: 7192982.
      View in: PubMed   Mentions:    Fields:    Translation:Humans